13.67
price up icon4.51%   0.59
pre-market  プレマーケット:  13.43   -0.24   -1.76%
loading
前日終値:
$13.08
開ける:
$13.21
24時間の取引高:
1.39M
Relative Volume:
0.72
時価総額:
$1.17B
収益:
$139.71M
当期純損益:
$-209.36M
株価収益率:
-4.6182
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
+8.49%
1か月 パフォーマンス:
+4.51%
6か月 パフォーマンス:
-40.77%
1年 パフォーマンス:
-33.90%
1日の値動き範囲:
Value
$13.15
$13.74
1週間の範囲:
Value
$12.40
$13.74
52週間の値動き範囲:
Value
$12.06
$25.34

Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile

Name
名前
Syndax Pharmaceuticals Inc
Name
セクター
Healthcare (1176)
Name
電話
781-419-1400
Name
住所
35 GATEHOUSE DRIVE, WALTHAM, MA
Name
職員
184
Name
Twitter
@syndax
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
SNDX's Discussions on Twitter

SNDX を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SNDX
Syndax Pharmaceuticals Inc
13.67 1.17B 139.71M -209.36M -160.60M -2.96
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-10-24 開始されました UBS Buy
2024-06-28 開始されました Jefferies Buy
2024-01-31 ダウングレード Scotiabank Sector Outperform → Sector Perform
2023-12-22 開始されました Mizuho Buy
2023-10-25 開始されました BofA Securities Buy
2023-10-11 開始されました Goldman Buy
2023-07-27 開始されました Scotiabank Sector Outperform
2023-07-11 開始されました Guggenheim Buy
2023-04-17 再開されました BTIG Research Buy
2023-01-31 開始されました Stifel Buy
2023-01-03 開始されました JP Morgan Overweight
2022-07-28 再開されました B. Riley Securities Buy
2022-04-11 開始されました H.C. Wainwright Buy
2022-02-15 開始されました Goldman Buy
2021-06-04 再開されました Robert W. Baird Outperform
2021-05-25 開始されました Citigroup Buy
2021-02-18 開始されました B. Riley Securities Buy
2020-12-03 開始されました Stifel Buy
2020-05-22 アップグレード Citigroup Neutral → Buy
2020-05-22 ダウングレード H.C. Wainwright Buy → Neutral
2020-05-18 ダウングレード Citigroup Buy → Neutral
2020-05-11 繰り返されました H.C. Wainwright Buy
2020-03-04 開始されました Barclays Overweight
2020-01-13 繰り返されました H.C. Wainwright Buy
2019-03-08 繰り返されました H.C. Wainwright Buy
2019-01-04 開始されました Robert W. Baird Outperform
2018-01-05 開始されました B. Riley FBR, Inc. Buy
2017-03-16 開始されました FBR & Co. Outperform
2017-03-02 開始されました Instinet Buy
2016-10-07 開始されました Guggenheim Buy
2016-03-28 開始されました Citigroup Buy
2016-03-28 開始されました JMP Securities Mkt Outperform
2016-03-28 開始されました Morgan Stanley Overweight
すべてを表示

Syndax Pharmaceuticals Inc (SNDX) 最新ニュース

pulisher
Jan 21, 2025

Syndax Stock Looks Tantalizing, But Looks Can Be Deceptive (NASDAQ:SNDX) - Seeking Alpha

Jan 21, 2025
pulisher
Jan 18, 2025

Syndax Pharmaceuticals (FRA:1T3) Net-Net Working Capital : €3.67 (As of Sep. 2024) - GuruFocus.com

Jan 18, 2025
pulisher
Jan 17, 2025

How the (SNDX) price action is used to our Advantage - Stock Traders Daily

Jan 17, 2025
pulisher
Jan 17, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Short Interest Update - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Syndax Pharmaceuticals (FRA:1T3) Price-to-Operating-Cash-Fl - GuruFocus.com

Jan 17, 2025
pulisher
Jan 17, 2025

Syndax Pharmaceuticals (FRA:1T3) ROE % Adjusted to Book Val - GuruFocus.com

Jan 17, 2025
pulisher
Jan 17, 2025

Assenagon Asset Management S.A. Has $27.29 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Jan 17, 2025
pulisher
Jan 17, 2025

Incyte, Syndax get FDA okay for 9 mg, 22 mg Niktimvo vials - MSN

Jan 17, 2025
pulisher
Jan 15, 2025

Incyte's and Syndax's Graft Disease Treatment Niktimvo Gets FDA Approval for Vial Sizes - Marketscreener.com

Jan 15, 2025
pulisher
Jan 15, 2025

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvotm (axatilimab-csfr) 9 mg and 22 mg Vial Sizes - Lelezard

Jan 15, 2025
pulisher
Jan 15, 2025

FDA Approves Niktimvo: Breakthrough Treatment for Chronic GVHD Shows 75% Response Rate - StockTitan

Jan 15, 2025
pulisher
Jan 15, 2025

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs - Investing.com Nigeria

Jan 15, 2025
pulisher
Jan 15, 2025

Syndax Pharmaceuticals (FRA:1T3) Cash From Discontinued Inv - GuruFocus.com

Jan 15, 2025
pulisher
Jan 15, 2025

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid AML breakthroughs By Investing.com - Investing.com South Africa

Jan 15, 2025
pulisher
Jan 14, 2025

SNDX stock touches 52-week low at $12.38 amid market challenges - Investing.com Nigeria

Jan 14, 2025
pulisher
Jan 14, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 1-Year LowHere's Why - MarketBeat

Jan 14, 2025
pulisher
Jan 13, 2025

Syndax Achieves Dual FDA Approvals for Breakthrough Cancer & GVHD Treatments in Major Growth Milestone - StockTitan

Jan 13, 2025
pulisher
Jan 13, 2025

Syndax Pharmaceuticals (FRA:1T3) Other Current Receivables : €4.23 Mil (As of Sep. 2024) - GuruFocus.com

Jan 13, 2025
pulisher
Jan 10, 2025

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain - Yahoo Finance

Jan 10, 2025
pulisher
Jan 09, 2025

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid challenges - Investing.com India

Jan 09, 2025
pulisher
Jan 08, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Given New $16.00 Price Target at Scotiabank - MarketBeat

Jan 08, 2025
pulisher
Jan 08, 2025

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm - The Eastern Progress Online

Jan 08, 2025
pulisher
Jan 07, 2025

Where are the Opportunities in (SNDX) - Stock Traders Daily

Jan 07, 2025
pulisher
Jan 07, 2025

Syndax Pharmaceuticals CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan

Jan 07, 2025
pulisher
Jan 06, 2025

Jefferies maintains Buy rating on Syndax stock with $43 target By Investing.com - Investing.com Nigeria

Jan 06, 2025
pulisher
Jan 03, 2025

Syndax Pharmaceuticals Awards 123,100 Stock Options to New Hires in Growth Initiative - StockTitan

Jan 03, 2025
pulisher
Dec 31, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Up 4.1%What's Next? - MarketBeat

Dec 31, 2024
pulisher
Dec 29, 2024

Stifel Financial Corp Purchases Shares of 16,976 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Dec 29, 2024
pulisher
Dec 28, 2024

Analysts Set Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Price Target at $36.90 - MarketBeat

Dec 28, 2024
pulisher
Dec 28, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World

Dec 28, 2024
pulisher
Dec 27, 2024

SNDX stock touches 52-week low at $12.75 amid market challenges - Investing.com Canada

Dec 27, 2024
pulisher
Dec 26, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Sets New 1-Year LowWhat's Next? - MarketBeat

Dec 26, 2024
pulisher
Dec 25, 2024

Syndax Pharmaceuticals, Inc. Announces Cessation of Catherine Madigan as Chief Medical Officer - Marketscreener.com

Dec 25, 2024
pulisher
Dec 25, 2024

Geode Capital Management LLC Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Dec 25, 2024
pulisher
Dec 25, 2024

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by Geode Capital Management LLC - MarketBeat

Dec 25, 2024
pulisher
Dec 24, 2024

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 2.6%Should You Sell? - MarketBeat

Dec 24, 2024
pulisher
Dec 23, 2024

Barclays PLC Purchases 110,535 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Dec 23, 2024
pulisher
Dec 22, 2024

Syndax Pharmaceuticals CMO position eliminated By Investing.com - Investing.com Canada

Dec 22, 2024
pulisher
Dec 22, 2024

Syndax Pharmaceuticals CMO position eliminated - Investing.com

Dec 22, 2024
pulisher
Dec 19, 2024

Syndax Pharmaceuticals' SWOT analysis: stock poised for growth amid FDA approvals - Investing.com

Dec 19, 2024
pulisher
Dec 19, 2024

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors - cnhinews.com

Dec 19, 2024
pulisher
Dec 19, 2024

Franklin Resources Inc. Has $34.95 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Dec 19, 2024
pulisher
Dec 19, 2024

SNDX stock touches 52-week low at $13.26 amid market challenges - Investing.com Canada

Dec 19, 2024
pulisher
Dec 18, 2024

State Street Corp Increases Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

Dec 18, 2024
pulisher
Dec 17, 2024

Fmr LLC Has $948,000 Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - Defense World

Dec 17, 2024
pulisher
Dec 17, 2024

Syndax Pharmaceuticals' SWOT analysis: biotech stock poised for growth amid challenges - Investing.com India

Dec 17, 2024

Syndax Pharmaceuticals Inc (SNDX) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):